FindTrial
Sign In

Clopidogrel & Aspirin, Prasugrel & Aspirin

DRUG2 trials

Sponsors

Cordis US Corp., Baim Institute for Clinical Research

Conditions

Coronary Artery Disease

Phase 4

CYPRESS - CYPHER for Evaluating Sustained Safety
NCT00954707
Cordis US Corp.Coronary Artery Disease
Start: 2009-08-31End: 2016-03-31Updated: 2014-02-07
The Dual Antiplatelet Therapy Study (DAPT Study)
CompletedNCT00977938
Baim Institute for Clinical ResearchCoronary Artery Disease
Start: 2009-10-31End: 2014-06-30Updated: 2017-06-09

Related Papers

Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Journal of the American Heart Association2023-07-146 citations
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.
2021-04-019 citations
Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women
Circulation Cardiovascular Interventions2018-08-0115 citations
Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
2017-10-0192 citations
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting
JAMA Cardiology2017-03-1526 citations
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)
Circulation2017-02-2321 citations
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study
Circulation2016-08-3122 citations
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
2016-04-0163 citations
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
JAMA2016-03-29897 citations
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study
Circulation2016-03-1949 citations
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
2016-01-0140 citations
Causes of late mortality with dual antiplatelet therapy after coronary stents
European Heart Journal2015-11-1850 citations
Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
2015-10-0131 citations
Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents
JAMA2015-03-1790 citations
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
2015-03-15200 citations
Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial
Circulation Cardiovascular Quality and Outcomes2014-11-1720 citations
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
New England Journal of Medicine2014-11-161872 citations